Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824405 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
A Phase 2 study, sponsored by Botanix Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT03824405 is a Phase 2 study that has completed, run by Botanix Pharmaceuticals. The registered enrollment target is 200 participants.
The verdict
NCT03824405, a Phase 2 study, has completed, sponsored by Botanix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.
Interventions
- DRUG Vehicle
- DRUG BTX 1204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2020-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03824405
The ClinicalTrials.gov registry entry for NCT03824405 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Botanix Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT03824405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03824405 about?
NCT03824405 is a clinical study titled "Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis". This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.
What is the current status of trial NCT03824405?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2019-02-04. Estimated completion is 2020-03-04.
What interventions are being tested in trial NCT03824405?
The interventions under investigation include: Vehicle (DRUG), BTX 1204 (DRUG).
Who is sponsoring clinical trial NCT03824405?
This trial is sponsored by Botanix Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.